

**Company registration number: 60460**

**Muscular Dystrophy Society of Ireland CLG  
(A Company Limited by Guarantee and not having Share Capital)**

**Financial statements**

**for the financial year ended 31 December 2018**

---

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Contents**

	<b>Page</b>
Trustees and other information	<b>1</b>
Trustees report	<b>2 - 13</b>
Trustees responsibilities statement	<b>14</b>
Independent auditor's report to the members	<b>15 - 17</b>
Statement of financial activities	<b>18</b>
Statement of financial position	<b>19 - 20</b>
Statement of cash flows	<b>21</b>
Notes to the financial statements	<b>22 - 35</b>

---

**Muscular Dystrophy Society of Ireland CLG**  
**Company limited by guarantee**

**Directors and other information**

<b>Trustees</b>	Garry Toner Helen McDonnell (Resigned 5th February 2018) Hazel Bridcut Ephraim Purcell John Roche Grace Greene Tom Nolan (Appointed 23rd June 2018 , Resigned 24th July 2018) Anne Horan (Appointed 23rd June 2018, Resigned 10th August 2018) Kenneth Rowan (Co-opted 13th August 2018)
<b>Secretary</b>	Hazel Bridcut
<b>Company number</b>	60460
<b>Registered office</b>	Muscular Dystrophy Society of Ireland CLG 75 Lucan Road Chapelizod Dublin 20
<b>Business address</b>	75 Lucan Road Chapelizod Dublin 20
<b>Auditor</b>	Hunt & Company Accountants Limited 52 Manor Street Dublin 7
<b>Bankers</b>	Bank of Ireland 2 College Green Dublin 2
<b>Solicitors</b>	Sherrys Solicitors Palmerstown Avenue Palmerstown Dublin 20
<b>Charity Regulator Number</b>	20012038

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report**

The trustees present their annual report and the audited financial statements of the company for the financial year ended 31 December 2018.

The directors of the company are also the charity's trustees.

**Business name**

The business name of the company is Muscular Dystrophy Ireland.

**Trustees**

The names of the persons who at any time during the financial year were trustees of the company are as follows:

Garry Toner

Helen McDonnell ( Resigned 5th February 2018)

Hazel Bridcut

Ephraim Purcell

John Roche

Grace Greene

Tom Nolan (Appointed 23rd June 2018 , Resigned 24th July 2018)

Anne Horan (Appointed 23rd June 2018, Resigned 10th August 2018)

Kenneth Rowan (Co-opted 13th August 2018)

**Principal activities**

The principal activity of the company is to provide information, advice and support to people with Muscular Dystrophy and allied neuromuscular conditions, and their families through a range of support services.

**Mission Statement**

Muscular Dystrophy Ireland aims to provide information and support to people with neuromuscular conditions and their families through a range of support services. Muscular Dystrophy Ireland's Objective is to promote through practical empowerment, independent living for people with the condition muscular dystrophy.

Muscular Dystrophy Ireland supports advocating for services to enable people with neuromuscular conditions to fully participate in society and to live a life of their own choosing. Muscular Dystrophy Ireland also aims to support and fund research into neuromuscular conditions.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**STRUCTURE, GOVERNMENT AND MANAGEMENT**

**The Council and Board**

Muscular Dystrophy Ireland is conducted in accordance with its Memorandum and Articles of Association which were adopted in November 1977 and amended up to and including 29th May 2009.

Muscular Dystrophy Ireland is directed by a voluntary Board which is known as the Executive Committee. The Executive Committee comprises a Chairperson, Vice Chairperson, Treasurer, Secretary and there is allocation for a further three members. This Executive Committee meets once a month to determine the management, good governance and financial control of Muscular Dystrophy Ireland. The Executive is provided with regular financial and operational information.

The Executive Committee met on 10 occasions during the year

The Executive Committee travel expenses in attending meetings in 2018 were €509.

The governance structure of Muscular Dystrophy Ireland is unusual in that instead of a Board there is a National Executive and a National Council who share the same officers. The National Executive members who also sit on the National Council, are charged with managing the business and are directors of the company.

Expert legal opinion has determined that both the members of the National Executive and the members of the National Council share the same legal obligations, accountabilities and liabilities.

A review was carried out in 2017 to ensure that Muscular Dystrophy Ireland's governance structure remains compliant with the Companies Act 2014 and the Charities Act 2009 and the formal establishment of the Charities Regulator. This review was ongoing in 2018 and The Board will report to the members at Annual General Meeting in June 2019.

The following committees are appointed by The Executive to assist in the operational workings of the organisation.

Finance and Audit Committee  
Research Committee  
Trust Fund Committee

**Management**

Muscular Dystrophy Ireland has six regional offices, in Cork, Donegal, Galway, Mullingar, Kells, Carlow and Limerick. There is also a Muscular Dystrophy Ireland staff member based in the southeast region. Family support is available throughout all HSE regions of Ireland, while youth support is available in the east, south, west, midlands, northeast, northwest, and southeast.

The Chief Executive is responsible for the day to day management and operation of the organisation throughout the National Office and Regional Offices. The National Office is the base for all administration and support services of the organisation.

During the year under review the Chief Executive position was held in the interim by Ms Elaine McDonnell.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**Charities Governance Code**

This governance code is issued by the Charities Regulator under section 14(1) (i) of the Charities Act 2009, to encourage and facilitate the better administration and management of charitable organisations.

**FUNDING**

Muscular Dystrophy Ireland provides services under Service Level Arrangements with eight CHO Areas. Counselling and Bereavement services were funded through TUSLA. Employee Supports was funded through the Department of Social Protection Wage Subsidy Scheme (WSS). Funding from the HSE represented 80% of overall incoming resources for 2018.

**OTHER INCOMING RESOURCES**

In line with other Charities, Muscular Dystrophy Ireland receives goods, services and facilities free of charge or at reduced rates. During the period under review, Muscular Dystrophy Ireland received material goods, services and facilities to the value of €11,200 free of charge and this value has been incorporated into the financial statements for 2018.

**RESERVES**

Muscular Dystrophy Ireland has a Reserve Policy which is reviewed each year. Muscular Dystrophy Ireland has free reserves at 31st December 2018 which can be expended at the discretion and agreement of The Board in furtherance of the objectives of Muscular Dystrophy Ireland. Muscular Dystrophy Ireland has restricted reserves at 31st December 2018 which can only be expended for the particular purposes specified by donors.

Formal Reserve Policy was agreed and signed by the Board at meeting held on the 23rd April 2018.

**Policy States:**

The Board has set a Reserves Policy which requires:-

Reserves to be maintained at a level which ensures that Muscular Dystrophy Ireland's core activities could continue during a period of unforeseen difficulty equivalent to six months core funding

A proportion of reserves to be maintained in a readily realisable form.

**REVIEW OF ACTIVITIES**

**Information**

A key function of Muscular Dystrophy Ireland is to provide accurate and relevant information to people with neuromuscular conditions, their families, healthcare and education professionals and the general public. Muscular Dystrophy Ireland's Information Officer is based in the Head Office in Dublin and provides a nationwide service.

In 2018, over 320 individual requests for information were processed. These come from people who are newly diagnosed or their family members or from those who were diagnosed some time ago and now feel that they need some information or support. In some circumstances, the Information Officer is the first point of contact for persons new to the organisation following a diagnosis of a neuromuscular condition and information packs were sent to families new to the organisation.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**Muscular Dystrophy Ireland's Presentations / Information Talks**

Muscular Dystrophy Ireland's Information Officer is also available to give presentations about Muscular Dystrophy and neuromuscular conditions to schools, medical professionals and students etc. Educating allied and emerging health professionals is an important part of the work Muscular Dystrophy Ireland does in creating awareness of Neuromuscular Conditions

On the 23rd June 2018 Muscular Dystrophy Ireland organised a National Conference and AGM in The Midlands Park Hotel, Portlaoise, Co. Laois. The Agenda included presentations on the Strategic Plan and the proposed Registry of people with Muscular Dystrophy and was followed by a workshop on Entitlements for people with disabilities.

The Information Officer also attends conferences on a range of topics and Conditions and reports this information back to members. In 2018, the Information Officer attended the European Conference for Rare Diseases on the 10th-12th May and the Rare Disease Symposium on 3rd May 2018. The Organisation was also represented at the Join Our Boys Conference on 6th October 2018.

The Information Officer gave a presentation on the condition to Neurologists who met in Cork on 24th May 2018.

**Advocacy**

Patient Advocacy and Influencing Policy has become an increasing part of Muscular Dystrophy Ireland's Information Service. Much of this advocacy was focussed on access to the new and innovative treatments now available for Muscular Dystrophy.

During 2018, Muscular Dystrophy Ireland continued to work with families who were campaigning to have access to Translarna for their sons.

A new treatment for people with SMA, Spinraza was being considered by the HSE. During 2018, Muscular Dystrophy Ireland has provided support and help to the group of families campaigning for access to this drug. This includes facilitating a meeting on 9th August 2018 for families affected by this issue. A protest was held at the Dail on September 20th 2018 and there is an ongoing media campaign to highlight the issue

**Newsletter**

The Muscular Dystrophy Ireland News Update is a newsletter for members of Muscular Dystrophy Ireland and their families and friends. It includes articles about issues of interest to people affected by the condition, research updates, articles on entitlements and holidays, photographs and reports on youth clubs and Muscular Dystrophy Ireland events such as conferences and fundraising events.

Four high quality editions of the newsletter were produced and distributed during 2018. Each edition is posted to approximately 750 people and a further 1,000 are sent via email. The newsletter is also available on our website [www.mdi.ie](http://www.mdi.ie)

**Social Media**

Muscular Dystrophy Ireland manages two main social media accounts and has amassed a significant following on Facebook with over 6,000 followers and almost 2,000 on Twitter



**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**Family Support Services**

Muscular Dystrophy Ireland offers family support service to families nationwide. The aim of the Family Support Team is to support families from diagnosis right through to bereavement. They promote, encourage and advocate for independent decision making by the members in keeping with the Muscular Dystrophy Ireland ethos.

The Role of the Family Support Team is to provide a quality service which best meets the varied needs of Muscular Dystrophy Ireland members.

The Family Support Team provides a range of information and support services to include: -

- Phone support
- Home visits
- Support and Social Groups
- Bereavement Support
- Emotional Support
- Help and advocacy with entitlements
- Interaction with Health and Social Care professionals
- Attendance at Case Conferences
- Counselling referrals
- Provision of information in relation to entitlements, health, housing and education

The Family Support Service is also used by Health professionals, including Public Health Nurses, Physiotherapists, G.P.s, schools, clinics, other organisations and service providers

**RESPITE SERVICES**

The respite service is an essential support for people living with muscular dystrophy and their families.

**Muscular Dystrophy Ireland Definition of Respite:**

Respite care is short-term care that enables a family take a break from the daily caring role. Respite care can occur in the family home or in a variety of out-of-home settings, and can occur for any length of time depending on the needs of the family, and resources available. Muscular Dystrophy Ireland recognises that the person/child with muscular dystrophy and family members both need to avail of respite care services in order to maintain physical health and emotional wellbeing.

**The respite services include:**

1. Personal Assistant Services
2. Family Support Services
3. Six Respite Holiday Camps
4. Youth Services
5. Power Soccer Support
6. Adult Social Services
7. Transport Services
8. Counselling

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**Personal Assistant and in-home respite hours provided in 2018:**

7,467 hours provided by Muscular Dystrophy Ireland Personal Assistants (12,628 hours provided in 2017)

1,084 hours through external agencies (IWA, CIL, Bluebird, Home Instead etc.) (1,120 hours provided in 2017)

4,823 hours provided to support Respite Holiday Programme (3,538 hours provided in 2017)

A total of 13,374 respite hours in 2018 (17,286 hours in 2017)

38 members received a personal assistant or in-home respite support.

65 members benefited from personal assistant support on Respite Holiday Programme

Respite hours vary on an annual basis according to members' needs and requirements. In 2018 there was an increase in the number of members receiving respite support services. However, the actual hours provided fell due to the completion of a number of respite support services under which Muscular Dystrophy Ireland had been facilitating the delivery of members' personal assistance support. This equated to approximately 8,000 support hours.

Overall, the number of families seeking support services increased during 2018 with particular demand for Personal Assistant hours and Counselling and Bereavement Services.

**Youth Respite Services**

The overall aim of the Muscular Dystrophy Ireland Youth Service is the empowerment of our young members.

The specific aims of the Muscular Dystrophy Ireland Youth Work Programme are as follows: -

- To empower our young members
- To encourage meaningful participation
- To provide an educational aspect
- To promote equality of opportunity
- To provide respite for parents and siblings

Youth workers support, encourage and enable our young members to get out and about in their communities. Through our youth clubs, social outings and camps, members have the opportunity to make friends and maintain friendships already made. The peer support that is both given and received is invaluable. Involvement in the Youth Services is for the most part, the first stride towards independence for members.

On Thursday, 1st November 2018, the Virtual Reality Party Mobile came to Dundalk for a day of escaping reality. Eight members and siblings attended and really enjoyed it. There was an endless list of possibilities from riding a rollercoaster to being a Ninja or a space invader. It was an amazing day for members and a chance to experience things they may not have done before.

Other youth activities that took place were:

- Siblings Days
- Mondello Park
- Confidence building workshop
- Workshops in pottery, cookery and film making
- Visits to Fota Wildlife Park, Blarney Castle, Butlers Chocolate Factory, Lullymore, Slieve Gullion, Glendeer Pet Farm and Dreamland

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**Respite Holiday Programme**

Muscular Dystrophy Ireland continues to develop the Respite Holiday Programme each year and in 2018 six respite breaks were held in Kilcuan, Clarinbridge, Co. Galway. A minicamp was also held in the Home from Home for members who were going away on camp for the first time.

In total 65 members participated in the Respite Holiday Programme during 2018.

The Respite Holiday Programme provides an invaluable service to members and families by providing a respite break not only for the member, but the families, parents and siblings.

**Home from Home Apartment**

2018 has been the busiest year to date for the Home from Home Apartment. During the year, we provided accommodation for over 821 guests from 439 bookings (2017 - 700 guests). With the assistance of funding from Monkstown Hospital Foundation, Orlaith Humphrey's Fund, AVIVA Community Fund and SMBC Capital Aviation we completed a number of upgrades to the interior of the apartment. These included, Security Camera System throughout the premises, a new Jacuzzi bath in room 3, Geberit Aqua Clean 8000 Toilet in bathroom 2, refurbishment of all the profile beds and service of all ceiling hoists. In addition the apartment was painted throughout and this work was all completed in the first quarter of 2018.

Towards the end of 2018, Muscular Dystrophy Ireland received a donation from United Hardware Ltd. of 200 sq. metres of high quality laminated flooring. This flooring will be used to replace the current carpet tiles.

The apartment continues to offer many of our guests the opportunity to experience Independent Living by taking a short break outside the walls of institutional living. This service has been appreciated by the organisations which have regularly used the apartment for respite during the year. Some of the groups still enjoying the facilities are Cheshire Home, Enable Ireland, Ataxia Ireland, St. John of Gods and the Brothers of Charity.

The feedback we received from our clients is crucial in regards to how we endeavour to meet the needs of service users in the future.

The international visitors have come from many different countries which have included France, UK, Germany, USA and Denmark. Their feedback has been extremely positive and it is always vital to have an international perspective on some of the services we are providing.

In November 2018, the Muscular Dystrophy Ireland Home from Home Facility received a renewed Bord Failte Four Star rating for the year.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**Training and Boardroom Hire**

The Boardroom has been used by several different organisations for their management meetings and community activities. This allows organisations to have a facility that meets their needs and provides access for all their membership. The groups that have used our building during 2018 are diverse; they have included Lucan Disability Action Group, Post-Polio Support Group, Disabled Drivers Association, Ataxia Federation Ireland and many others.

Throughout 2018 the Boardroom has been promoted as a training facility. We have continued our relationship with Ballyfermot Senior College and Clondalkin College of Further Education by providing Manual Handling training to all their Social Care students.

**Transport**

Over the years Muscular Dystrophy Ireland has built up a transport fleet that covers the whole country. The transport service is co-ordinated by the Driver / Transport Coordinator based in Muscular Dystrophy Ireland's Head Office.

The transport service in the Leinster area is categorised into four headings as follows:

Hospital/Clinic transport  
Social/Respite transport  
Educational/Employment/Training transport  
Equipment drop off/collection

In areas where there is no dedicated staff member to provide transport, we use third party providers to carry out services on our behalf

Muscular Dystrophy Ireland's buses are used by Youth Workers to provide transport and carry out daily respite and youth work activities. There is currently a fleet of eleven buses operating nationwide.

In 2018 there were two dedicated drivers who provided a transport service to members with a total of 1,470 journeys undertaken providing the service to 2,121 passengers

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**RESEARCH**

One of Muscular Dystrophy Ireland's aims is to fund and support research relating to muscular dystrophy. This includes biomedical research, which looks at what happens in the body when someone has muscular dystrophy, or identifies potential therapies. It also includes social research, which examines issues like education and quality of life.

In 2018 Muscular Dystrophy Ireland continued to fund medical research through the direct funding of a project in Maynooth University. Two further projects are co-funded via the Collagen VI Alliance in Newcastle University and the Rizzoli Orthopaedic Institute, Bologna. Work continued on the two research projects co-funded by Muscular Dystrophy Ireland and grants from The Health Research Board and Medical Research Charities Group Joint Funding Scheme (2017). This research was conducted in Maynooth University and Oxford University. Both projects receive 50% funding from the HRB and 50% funding from the charity and received continued financial support from Muscular Dystrophy Ireland in 2018.

In early 2018 Muscular Dystrophy Ireland conducted a review of patient registries with the short to medium term view of setting up a Neuromuscular Disease Registry for Ireland which could become self-sustainable in the long run. One of the main reasons for a registry is to identify potential candidates for clinical trials. The outcome of the Muscular Dystrophy Ireland review was that the Irish NMD Registry should be modelled on the New Zealand Registry. The curator of the New Zealand registry, Ms M J Rodrigues, visited Muscular Dystrophy Ireland in early June 2018 and made a short presentation to the Muscular Dystrophy Ireland Research Committee. Investigation into the setting up an Irish NMD Registry is ongoing.

**FUNDRAISING AND PUBLIC RELATIONS**

Fundraising is an essential part of Muscular Dystrophy Ireland's activities, supporting the continued provision of respite support services, medical research, as well as the Home from Home Facility.

Muscular Dystrophy Ireland acknowledges the wonderful support which it continues to receive from members, families, supporters and volunteers.

**Highlights of Fundraising Campaigns 2018**

LoveMDI Campaign  
Ireland Bikefest Raffle  
Tesco Collection Day  
VHI Women's Mini Marathon  
Evening Echo Women's Mini Marathon  
Christmas Fundraising Campaign  
Xilinx CSR Fund for Summer Camps  
Aviva Broker's CSR Fund for Home From Home Apartment  
SMBC Aviation CSR Fund for Home From Home Apartment  
Trivago CSR Fund for Home From Home Apartment

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees report (continued)**

**MAJOR RISKS FACING THE ORGANISATION**

The Executive Committee are responsible for ensuring that the major risks facing the organisation are appropriately managed. During the year the major risks facing the organisation as identified by the Executive Committee and Management have been reviewed and their potential impact assessed. Policy and Procedures are in place to identify the risks facing the organisation taking into account the financial climate, changes in society and attitudes which reflect how the organisation operates and changes in law and technology. In particular expenditure across all areas has been reviewed in the light of a decrease in state funding and the uncertainty of a fundraising income.

**FUTURE DEVELOPMENTS**

The Strategic Planning process is underway. The Strategic Plan will specifically focus on key components of the organisation's vision, structure, services and activities. In 2018 meetings were held with staff, Board and members to ascertain their views. Submissions were also taken from individual members and surveys were filled in by stakeholders.

It is hoped that the Strategic Plan will be presented to the members at the AGM in 2019.

Muscular Dystrophy Ireland will continue to strengthen the governance and regulation of the organisation to ensure compliance with relevant regulatory bodies.

Muscular Dystrophy Ireland will continue to contribute to national and international research led by our Research Committee.

Muscular Dystrophy Ireland has commenced work on upgrading and developing a new website and it will be completed in 2019.

Following completion of the Strategic Plan and taking into account reporting requirements of stakeholders and other funders, Muscular Dystrophy Ireland will carry out an extensive review of our current database with a view to implementing an integrated CRM system which accurately records our inputs, outcomes and impact of the very valuable work which is undertaken by the Trustees, Staff and Volunteers of Muscular Dystrophy Ireland.

Ongoing specific goals for 2019: -

- Ensure Website, Database and IT Technology are compliant with GDPR statutory obligations
- Continued engagement on Social Media Platforms to enhance communications with members, staff and stakeholders
- Continue to build on Corporate Partnerships
- Explore and develop Fundraising opportunities
- Continue Professional Development and Training Programme for staff which commenced in 2017.
- Expansion of Board to enhance and complement existing skills and experience
- Continue work on a self-advocacy toolkit for members
- Research committee to focus on the development of a neuromuscular patient registry.
- Begin the process of upgrading the fleet of buses with the purchase of two new buses in 2019

**Accounting records**

The measures taken by the trustees to secure compliance with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at its registered office



**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Trustees responsibilities statement**

The trustees are responsible for preparing the trustees report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the trustees to prepare financial statements for each financial year. Under the law, the trustees have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The trustees are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and trustees report comply with the Companies Act 2014 and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



**Independent auditor's report to the members of  
Muscular Dystrophy Society of Ireland CLG**

**Report on the audit of the financial statements**

***Opinion***

We have audited the financial statements of Muscular Dystrophy Society of Ireland CLG (the 'company') for the financial year ended 31 December 2018 which comprise the statement of financial activity, statement of financial position, statement of cash flows and notes to the financial statements, including a summary of significant accounting policies set out in note 3. The financial reporting framework that has been applied in their preparation is Irish law and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland.

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2018 and of its surplus for the financial year then ended;
- have been properly prepared in accordance with FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland; and
- have been prepared in accordance with the requirements of the Companies Act 2014.

***Basis for opinion***

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

***Conclusions relating to going concern***

We have nothing to report in respect of the following matters in relation to which ISAs (Ireland) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

***Other Information***

The trustees are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Independent auditor's report to the members of  
Muscular Dystrophy Society of Ireland CLG (continued)**

***Opinions on other matters prescribed by the Companies Act 2014***

Based solely on the work undertaken in the course of the audit, we report that:

- in our opinion, the information given in the trustees' report is consistent with the financial statements; and
- in our opinion, the trustees' report has been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which we consider necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited, and financial statements are in agreement with the accounting records.

***Matters on which we are required to report by exception***

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

**Respective responsibilities**

***Responsibilities of trustees for the financial statements***

As explained more fully in the trustees' responsibilities statement, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

***Auditor's responsibilities for the audit of the financial statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**Independent auditor's report to the members of  
Muscular Dystrophy Society of Ireland CLG (continued)**

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

***The purpose of our audit work and to whom we owe our responsibilities***

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.



Raymond Hunt  
For and on behalf of  
Hunt & Company Accountants Limited  
Chartered Certified Accountants & Statutory Auditors  
52 Manor Street  
Dublin 7

21 May 2019

**Muscular Dystrophy Society of Ireland CLG**  
(A Company Limited by Guarantee and not having Share Capital)

**Statement of financial activities**  
for the financial year ended 31 December 2018

		Unrestricted Funds	Restricted Funds	Total Funds	Total Funds
		2018	2018	2018	2017
	Notes	€	€	€	€
<b>INCOMING RESOURCES</b>					
<b>Incoming resources from</b>					
<b>Voluntary Income</b>					
Donations and Fundraising		233,493	-	233,493	186,137
Subscriptions		4,375	-	4,375	4,020
<b>Incoming resources from</b>					
<b>charitable resources</b>					
Grants and other service contract income	5	-	1,200,399	1,200,399	1,272,986
Other income		31,244	10,979	42,223	54,826
<b>Investment income</b>	7	1,750	-	1,750	2,362
<b>Total Incoming resources</b>	4	<u>270,862</u>	<u>1,211,378</u>	<u>1,482,240</u>	<u>1,520,331</u>
<b>RESOURCES EXPENDED</b>					
<b>Cost of generating funds</b>					
<b>Cost of generating voluntary income</b>					
Public Relations, Awareness & Fundraising		32,118	53,409	85,527	100,529
<b>Charitable activities</b>					
Respite Care Services		147,300	1,087,787	1,235,087	1,284,220
Other		56,671	-	56,671	34,050
<b>Governance costs</b>		<u>33,846</u>	<u>30,442</u>	<u>64,288</u>	<u>40,518</u>
<b>Total resources expended</b>	4	<u>269,935</u>	<u>1,171,638</u>	<u>1,441,573</u>	<u>1,459,317</u>
<b>Net incoming/(outgoing) resources</b>		<u><u>927</u></u>	<u><u>39,740</u></u>	<u><u>40,667</u></u>	<u><u>61,014</u></u>

The financial statements were approved by the board on 20 May 2019 and signed on its behalf by  
On behalf of the board

Trustee  Purcell

Trustee  Hazel Bridcut

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Statement of financial position**  
**As at 31 December 2018**


	Note	2018 €	€	2017 €	€
<b>Fixed assets</b>					
Tangible assets	8	207,431		224,923	
Financial assets	9	1,589,111		1,589,111	
			<u>1,796,542</u>		<u>1,814,034</u>
<b>Current assets</b>					
Support group		241		6,592	
Debtors	10	93,382		98,129	
Investments	11	450,000		450,000	
Designated fund		101,223		101,223	
Restricted Trust and Research funds	16	662,655		664,486	
Cash at bank and in hand		599,760		582,746	
		<u>1,907,261</u>		<u>1,903,176</u>	
<b>Creditors: amounts falling due within one year</b>	12	<u>(89,636)</u>		<u>(120,197)</u>	
<b>Net current assets</b>			<u>1,817,625</u>		<u>1,782,979</u>
<b>Total assets less current liabilities</b>			<u>3,614,167</u>		<u>3,597,013</u>
<b>Creditors: amounts falling due after more than one year</b>	13		<u>(135,093)</u>		<u>(156,775)</u>
<b>Net assets</b>			<u><u>3,479,074</u></u>		<u><u>3,440,238</u></u>
<b>Capital and reserves</b>					
Restricted fund	16	880,380		842,471	
Unrestricted fund	16	2,598,694		2,597,767	
<b>Members funds</b>	16	<u><u>3,479,074</u></u>		<u><u>3,440,238</u></u>	

The notes on pages 22 to 35 form part of these financial statements.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Statement of financial position (continued)**  
**As at 31 December 2018**

These financial statements were approved by the board of trustees on 20 May 2019 and signed on behalf of the board by:

Trustee  Paul

Trustee  Hazel Bridcut

The notes on pages 22 to 35 form part of these financial statements.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Statement of cash flows**  
**Financial year ended 31 December 2018**

	2018	2017
	€	€
<b>Cash flows from operating activities</b>		
Net incoming/(outgoing) resources for the financial year	<b>40,667</b>	61,014
<i>Adjustments for:</i>		
Depreciation of tangible assets	<b>17,492</b>	17,395
Bank interest and Prize bond income	<b>(1,750)</b>	(2,362)
Accrued expenses/(income)	<b>(4,178)</b>	4,470
<i>Changes in:</i>		
Trade and other debtors	<b>11,098</b>	47,863
Trade and other creditors	<b>(48,065)</b>	(88,312)
Cash generated from operations	<b>15,264</b>	40,068
Net cash from operating activities	<b>15,264</b>	40,068
<b>Cash flows from investing activities</b>		
Purchase of tangible assets	-	(64,157)
Bank interest and Prize bond income	<b>1,750</b>	2,362
Capital funds movement	<b>(1,831)</b>	(34,863)
Net cash used in investing activities	<b>(81)</b>	(96,658)
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>15,183</b>	(56,590)
<b>Cash and cash equivalents at beginning of financial year</b>	<b>1,798,455</b>	1,855,045
<b>Cash and cash equivalents at end of financial year</b>	<b>1,813,638</b>	1,798,455

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements**  
**Financial year ended 31 December 2018**

**1. General information**

The company is a private company limited by guarantee, registered in Ireland. The address of the registered office is Muscular Dystrophy Society of Ireland CLG, 75 Lucan Road, Chapelizod, Dublin 20.

**2. Statement of compliance**

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

**3. Accounting policies and measurement bases**

**Basis of preparation**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in Euro, which is the functional currency of the entity.

**Support Groups**

The company had four regional support groups with the Donegal, Midlands and Kerry support groups closing during the year. South East support group is in the process of closing, following a full review of the structures and activities. The net incoming/(outgoing) resources of the regional support groups are not included in the Statement of Financial Activities.

**Tangible assets**

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.



**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**Depreciation**

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Office fit-out	- 20%
Fittings fixtures and equipment	- 20%
Ramp	- 4%
Motor vehicles	- 20%

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

**Financial assets**

Financial assets are initially recorded at cost, and subsequently stated at cost less any provision for diminution in value. Listed investments are measured at fair value with changes in fair value being recognised in profit or loss.

**Impairment**

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**Government grants**

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model and the performance model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**Financial instruments**

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

**Fund accounting**

**Restricted Funds:**

Restricted funds represent Grants and other funders which can only be used for the particular purposes specified by the donors. Such purposes are within the overall objectives of Muscular Dystrophy Ireland.

**Unrestricted Funds:**

Unrestricted funds represents amounts which are expendable at the discretion of the National Executive Committee, in furtherance of the objectives of Muscular Dystrophy Ireland.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**4. Incoming Resources/Resources Expended**

	2018	2017
	€	€
<b>Incoming Resources</b>		
Fundraising - National Office and Regional	94,592	97,333
Respite Care Services	1,200,399	1,272,986
MDI Centre	48,348	61,208
Donations	138,901	88,804
<b>Total Incoming Resources</b>	<u>1,482,240</u>	<u>1,520,331</u>
<b>Resources Expended</b>		
Fundraising - National Office and Regional	85,527	100,529
Respite Care Services (See Note below)	1,235,087	1,284,220
MDI Centre	56,671	34,050
Governance Costs - National and Regional	64,288	40,518
<b>Total Resources Expended</b>	<u>1,441,573</u>	<u>1,459,317</u>
<b>Net Incoming/(Outgoing) Resources</b>	<u>40,667</u>	<u>61,014</u>

Included in respite care services resources expended is an amount of €402,336. (2017 : €351,005) in relation to support costs.

**Net Incoming/(Outgoing) Resources**

	2018	2017
	€	€
The net incoming/(outgoing) resources for the year are stated after charging		
Depreciation of tangible assets	17,492	17,395
Auditors' remuneration	6,150	3,629
Bank interest & Prize bond income	<u>1,750</u>	<u>2,362</u>

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**5. Funding and Grants**

**HSE - Statutory Funding - Service Level Agreements**

**Purpose of Funding: Pay and Operational Costs**

**Term: Expires 31st December 2018**

**Restrictions on use: Core Charitable and Support Services**

**Funding received in the year ended 31st December 2018**

	2018	2017
	€	€
CHO Area 1 (North Western Area including Cavan Monaghan)	43,008	43,008
CHO Area 2 (Western Area )	11,000	11,000
CHO Area 4 (Southern Area )	91,251	91,251
CHO Area 5 (South Eastern Area )	10,740	10,740
CHO Area 6 (East Coast Area )	19,584	19,584
CHO Area 7 (South Western Area )	45,505	45,505
CHO Area 8 (Midlands Area including Louth Meath)	92,355	92,355
CHO Area 9 (Northern Area )	767,709	767,620
	<u>1,081,152</u>	<u>1,081,063</u>

**Funding expended in the year ended 31st December 2018**

Respite Pay Costs including pension contributions and Employers' PRSI	471,241	558,248
Support Pay Costs including pension contributions and Employers' PRSI	242,766	229,016
Respite Care Services Non Pay Costs	160,859	134,888
Communications	6,892	5,447
Utilities	3,412	5,069
Rent of regional offices	14,722	16,613
Support costs	110,461	98,704
Professional Fees:-		
HR Fees	13,130	10,763
Audit Fees	3,650	1,210
Pension Administration Fees	826	649
Data Protection	2,045	-
Governance costs	10,791	9,369
	<u>1,040,795</u>	<u>1,069,976</u>
Surplus	<u>40,357</u>	<u>11,087</u>

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**HSE - Direct Services - Service Level Agreements**  
**Purpose of Funding: Direct Support Services Provisions**  
**Term: Expires 31st December 2018**  
**Restrictions on use: Direct Services to Members**

**Funding received in the year ended 31st December 2018**

	<b>2018</b>	<b>2017</b>
	<b>€</b>	<b>€</b>
CHO Area 9 (Northern Area)	-	57,020
CHO Area 7 (South Western Area)	<b>47,660</b>	47,530
CHO Area1 (North Western Area)	<b>16,658</b>	16,046
CHO Area 6 (East Coast Area)	<b>1,240</b>	1,240
	<u><b>65,558</b></u>	<u>121,836</u>

**Funding expended in the year ended 31st December 2018**

Direct Services Pay Costs	<b>49,770</b>	104,126
Respite Support Services	<b>15,788</b>	-
Support and Training Costs	-	2,152
	<u><b>65,558</b></u>	<u>106,278</u>
 <b>Surplus</b>	 <u><b>-</b></u>	 <u>15,558</u>

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**HSE- National Lottery Funding**

**Purpose of Funding: Short Term Respite and Summer Respite Programme**

**Term: Expires 31st December 2018**

**Restrictions on use: Short Term Respite and Summer Respite Programme**

**Funding received in the year ended 31st December 2018**

	2018	2017
	€	€
CHO Area 1 (North Western Area including Cavan Monaghan)	2,000	3,250
CHO Area 2 (Western Area)	3,000	9,000
CHO Area 4 (Southern Area)	1,500	-
CHO Area 6 (East Coast Area)	4,000	-
CHO Area 7 (South Western Area )	9,000	10,000
CHO Area 8 (Midlands Area including Louth Meath Area)	15,200	12,000
CHO Area 9 (Northern Area)	11,000	11,800
	<b>45,700</b>	<b>46,050</b>

**Funding expended in the year ended 31st December 2018**

Short Term Respite	24,500	27,550
Summer Respite Programme	21,200	18,500
	<b>45,700</b>	<b>46,050</b>

Surplus

	-	-
--	---	---

	2018	2017
	€	€

**DSP Support Grant**

Employment Support Scheme	<b>5,789</b>	<b>22,818</b>
---------------------------	--------------	---------------

Other Grants

	2018	2017
	€	€

TUSLA - Counselling Support Services	2,200	2,200
Galway Co Council - Youth Service Equipment Grant	-	700
Limerick Institute of Technology- Intern Support Services	-	(1,681)
	<b>2,200</b>	<b>1,219</b>

	<b>1,200,399</b>	<b>1,272,986</b>
--	------------------	------------------

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**6. Staff costs**

	<b>2018</b>	<b>2017</b>
	<b>Number</b>	<b>Number</b>
Support Services	82	82
Operational Services	5	5
	<u>87</u>	<u>87</u>

The aggregate payroll costs incurred during the financial year were:

	<b>2018</b>	<b>2017</b>
	<b>€</b>	<b>€</b>
Wages and salaries	845,515	980,852
Pension costs	9,235	10,062
	<u>854,750</u>	<u>990,914</u>

The number of employees whose employment, excluding employer pension contributions, was greater than €65,000 are listed below:

	<b>2018</b>	<b>2017</b>
	<b>Number</b>	<b>Number</b>
€65,000 - €75,000	1	-
€75,000 - €85,000	-	-
€85,000 - €95,000	-	1

**Pension costs**

The company operates a defined contribution pension scheme. The scheme and its assets are held separately from those of the company in an independent administered fund with Aviva Life and Pensions UK Limited.

**7. Bank interest & Prize bond income**

	<b>2018</b>	<b>2017</b>
	<b>€</b>	<b>€</b>
Bank interest & Prize bond income	<u>1,750</u>	<u>2,362</u>



**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**8. Tangible assets**

	Office fit-out	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€	€
<b>Cost</b>				
At 1 January 2018	288,369	233,790	342,428	864,587
Additions	-	-	-	-
Disposals	-	-	-	-
<b>At 31 December 2018</b>	<u>288,369</u>	<u>233,790</u>	<u>342,428</u>	<u>864,587</u>
<b>Depreciation</b>				
At 1 January 2018	267,371	29,865	342,428	639,664
Charge for the financial year	8,995	8,497	-	17,492
<b>At 31 December 2018</b>	<u>276,366</u>	<u>38,362</u>	<u>342,428</u>	<u>657,156</u>
<b>Carrying amount</b>				
<b>At 31 December 2018</b>	<u>12,003</u>	<u>195,428</u>	<u>-</u>	<u>207,431</u>
At 31 December 2017	<u>20,998</u>	<u>203,925</u>	<u>-</u>	<u>224,923</u>

**9. Financial assets**

	Investments in Subsidiary	Total
	€	€
<b>Cost</b>		
At 1 January 2018 and 31 December 2018	<u>1,589,111</u>	<u>1,589,111</u>
<b>Provision for diminution in value</b>		
At 1 January 2018 and 31 December 2018	<u>-</u>	<u>-</u>
<b>Carrying amount</b>		
At 31 December 2018	<u>1,589,111</u>	<u>1,589,111</u>
At 31 December 2017	<u>1,589,111</u>	<u>1,589,111</u>

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**8. Financial assets (continued)**

**Muscular Dystrophy Ireland holds 100% of the share capital of the following company:**

Company	Country of registration or Incorporation	Class of share
MDI House Limited	Ireland	Ordinary

MDI House Limited's principal activity is that it owns the property at 75 Lucan Road, Chapelizod, Dublin 20 which is a purpose built facility to specifically cater for the requirements of people with Muscular Dystrophy and allied neuromuscular conditions, and their families.

In the opinion of the directors, the value to Muscular Dystrophy Ireland of the unlisted investment is not less than the book amount shown above, having regard to the service potential of the underlying property.

**10. Debtors**

	2018	2017
	€	€
Grants and Income due	62,388	70,778
Other debtors	830	1,542
Prepayments	30,164	25,809
	<u>93,382</u>	<u>98,129</u>

**11. Investments**

	2018	2017
	€	€
Investments in Prize Bonds	<u>450,000</u>	<u>450,000</u>

**12. Creditors: amounts falling due within one year**

	2018	2017
	€	€
Other creditors	20,258	27,517
Tax and social insurance:		
PAYE and social welfare	16,226	35,350
Accruals	53,152	57,330
	<u>89,636</u>	<u>120,197</u>

**Muscular Dystrophy Society of Ireland CLG**  
(A Company Limited by Guarantee and not having Share Capital)

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**13. Creditors: amounts falling due after more than one year**

	2018	2017
	€	€
Deferred Donations & Legacy Income (Note 14)	80,423	136,580
Deferred income (Note 14A)	54,670	20,195
	<b>135,093</b>	<b>156,775</b>

**14. Deferred Donations & Legacy income**

	Deferred at 1 Jan 2018	Received in 2018	Amortised in 2018	Deferred at 31 Dec 2018
	€	€	€	€
Donations	76,580	-	56,157	20,423
Legacy income	60,000	-	-	60,000
	<b>136,580</b>	<b>-</b>	<b>56,157</b>	<b>80,423</b>

**14A Deferred income**

	Deferred at 1 Jan 2018	Received in 2018	Amortised in 2018	Deferred at 31 Dec 2018
	€	€	€	€
Aviva - Home from Home	-	5,000	4,175	825
PTC - Therapeutic STRIVE Project	-	25,963	-	25,963
SMA Fund - SMA campaign	-	5,540	891	4,649
Other Funding - Support Services	20,195	5,207	2,169	23,233
	<b>20,195</b>	<b>41,710</b>	<b>7,235</b>	<b>54,670</b>

**15. Limited by guarantee**

The company is limited by guarantee and does not have a share capital. Each member has undertaken to contribute a sum not exceeding €1 in the event of its winding up.

**Muscular Dystrophy Society of Ireland CLG**  
(A Company Limited by Guarantee and not having Share Capital)

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**16. Equity Reserves**

	<b>Restricted Fund</b>	<b>Unrestricted Fund</b>	<b>Total</b>
	€	€	€
<b>At 1 January 2018</b>	842,471	2,597,767	3,440,238
Movements during the year	39,740	927	40,667
Other	(1,831)	-	(1,831)
<b>At 31 December 2018</b>	<u><u>880,380</u></u>	<u><u>2,598,694</u></u>	<u><u>3,479,074</u></u>

The movement in restricted funds in the year were as follows:-

<b>Restricted Fund</b>	<b>At start of year</b>	<b>Movement during year</b>	<b>At end of year</b>
	€	€	€
Research Fund	641,866	1,661	643,527
Trust Fund	22,620	(3,492)	19,128
Other	177,985	39,740	217,725
	<u><u>842,471</u></u>	<u><u>37,909</u></u>	<u><u>880,380</u></u>

Research Fund and Trust Fund consists of amounts received which can only be used for the purpose designated by Research and Trust Fund Committee.

Other restricted funds include funds received from HSE - Statutory Funding, National Lottery Funding and TUSLA Funding.

**17. Other financial commitments**

At 31 December 2018 the Company had no future commitments.

**18. Events after the end of the reporting period**

There were no subsequent events after year end.

**19. Related Party Transactions**

No related party transaction during the year.

**Muscular Dystrophy Society of Ireland CLG**  
**(A Company Limited by Guarantee and not having Share Capital)**

**Notes to the financial statements (continued)**  
**Financial year ended 31 December 2018**

**20. Approval of financial statements**

The board of trustees approved these financial statements for issue on 20 May 2019.